Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRĪ± and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.
Allegheny Health Network oncology experts delve into the latest information in the field of gynecologic oncology independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.
Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the ESMO Congress 2023 and the 2023 ASCO Annual Meeting, focusing on how these updates continue to shift clinical practice and advance care.